Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Indocyanine Green in Metastatic osteosarcoma: NCT07658768 Clinical Landscape Report 2026
9 min read
Indocyanine Green in Metastatic osteosarcoma: NCT07658768 Clinical Landscape Report 2026
16 September 2026
NCT07658768 clinical landscape for Metastatic osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Lutetium-177 EBRGD in Glioblastoma, IDH-Wildtype: NCT07655869 Clinical Landscape Report 2026
9 min read
Lutetium-177 EBRGD in Glioblastoma, IDH-Wildtype: NCT07655869 Clinical Landscape Report 2026
16 September 2026
NCT07655869 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Adalimumab biosimilar(Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd.) in Plaque psoriasis: NCT07663331 Clinical Landscape Report 2026
9 min read
Adalimumab biosimilar(Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd.) in Plaque psoriasis: NCT07663331 Clinical Landscape Report 2026
16 September 2026
NCT07663331 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ruxolitinib in Dermatitis, Atopic: NCT07661979 Clinical Landscape Report 2026
9 min read
Ruxolitinib in Dermatitis, Atopic: NCT07661979 Clinical Landscape Report 2026
16 September 2026
NCT07661979 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Cryptigens in Ovarian Cancer: NCT07665515 Clinical Landscape Report 2026
9 min read
Cryptigens in Ovarian Cancer: NCT07665515 Clinical Landscape Report 2026
16 September 2026
NCT07665515 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ocrelizumab in Multiple Sclerosis: NCT07667322 Clinical Landscape Report 2026
9 min read
Ocrelizumab in Multiple Sclerosis: NCT07667322 Clinical Landscape Report 2026
16 September 2026
NCT07667322 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Lidocaine in Uterine Cervical Cancer: PACTR202606770457238 Clinical Landscape Report 2026
9 min read
Lidocaine in Uterine Cervical Cancer: PACTR202606770457238 Clinical Landscape Report 2026
16 September 2026
PACTR202606770457238 clinical landscape for Uterine Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
Read →
GT737 in Relapsing acute myeloid leukemia: NCT07676006 Clinical Landscape Report 2026
9 min read
GT737 in Relapsing acute myeloid leukemia: NCT07676006 Clinical Landscape Report 2026
16 September 2026
NCT07676006 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
Read →
NeoOVIV vaccine (West China Hospital) in Ovarian Cancer: NCT07676890 Clinical Landscape Report 2026
9 min read
NeoOVIV vaccine (West China Hospital) in Ovarian Cancer: NCT07676890 Clinical Landscape Report 2026
16 September 2026
NCT07676890 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
RD-0605 in Idiopathic Inflammatory Myopathies: NCT07674147 Clinical Landscape Report 2026
9 min read
RD-0605 in Idiopathic Inflammatory Myopathies: NCT07674147 Clinical Landscape Report 2026
16 September 2026
NCT07674147 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
Read →
Dacarbazine in Melanoma, Cutaneous Malignant: NCT07671495 Clinical Landscape Report 2026
9 min read
Dacarbazine in Melanoma, Cutaneous Malignant: NCT07671495 Clinical Landscape Report 2026
16 September 2026
NCT07671495 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Dapagliflozin in Lupus Nephritis: NCT07678203 Clinical Landscape Report 2026
9 min read
Dapagliflozin in Lupus Nephritis: NCT07678203 Clinical Landscape Report 2026
16 September 2026
NCT07678203 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →